PTEN mutant samples were significantly enriched in BRCA1-, but not BRCA2-, deficient breast cancers compared to BRCA-proficient breast cancers (P = 2.8 x 10−3 and >0.99, respectively). This evidence concerns the gene PTEN and breast cancer.